Maxion Therapeutics utilizes its patented KnotBody® technology to develop engineered antibody therapeutics targeting ion channel and GPCR-driven diseases, which are often inadequately treated by existing small molecule drugs. The company focuses on creating safe, effective, and long-acting treatments for chronic pain, autoimmune disorders, and cardiovascular diseases, addressing a significant unmet medical need for over 1.8 billion patients worldwide.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing small molecule drugs often fail to effectively treat diseases driven by ion channel and GPCR dysfunction, leaving a significant unmet need for patients suffering from chronic pain, autoimmune disorders, and cardiovascular diseases. These traditional treatments often suffer from poor efficacy and off-target side effects.
Solution
Maxion Therapeutics is developing engineered antibody therapeutics using its patented KnotBody® technology to target ion channels and GPCRs. The KnotBody® technology combines naturally occurring cysteine-rich miniproteins with state-of-the-art antibody engineering techniques to create highly selective and potent therapeutics. This approach enables the development of safe, effective, and long-acting drugs against previously undruggable targets, offering a potential solution for diseases inadequately treated by existing small molecule drugs. The company aims to address the limitations of current treatments by leveraging the superior selectivity and proven therapeutic potential of engineered antibodies.
Target Audience
The primary target audience includes patients suffering from chronic pain, autoimmune disorders, and cardiovascular diseases, as well as pharmaceutical companies seeking novel therapeutic candidates for these conditions.
Features
- Patented KnotBody® technology for targeting ion channels and GPCRs
- Engineered antibodies with enhanced potency and selectivity
- Potential for long-acting therapeutic effects
- Multifunctional capabilities through Knottin fusion
- Improved manufacturability compared to traditional antibody approaches